Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex-mediated immune responses.
Blumberg, L.J., Humphries, J.E., Jones, S.D., Pearce, L.B., Holgate, R., Hearn, A., Cheung, J., Mahmood, A., Del Tito, B., Graydon, J.S., Stolz, L.E., Bitonti, A., Purohit, S., de Graaf, D., Kacena, K., Andersen, J.T., Christianson, G.J., Roopenian, D.C., Hubbard, J.J., Gandhi, A.K., Lasseter, K., Pyzik, M., Blumberg, R.S.(2019) Sci Adv 5: eaax9586-eaax9586
- PubMed: 31897428 
- DOI: 10.1126/sciadv.aax9586
- Primary Citation of Related Structures:  
6NHA - PubMed Abstract: 
The neonatal crystallizable fragment receptor (FcRn) functions as an intracellular protection receptor for immunoglobulin G (IgG). Recently, several clinical studies have reported the lowering of circulating monomeric IgG levels through FcRn blockade ...